RE-AKT: A trial looking at AZD5363 and enzalutamide for advanced prostate cancer
What is the study about?
RE-AKT investigates whether a new combination of drugs can help treat people with advanced prostate cancer.
Naturally occurring hormones encourage the growth of prostate cancer. People with prostate cancer receive treatment to block the action of these hormones, but this treatment can stop working. RE-AKT investigates whether a different type of hormone blocker called enzalutamide can help slow down cancer growth in combination with a new drug called capivasertib (AZD5363). Capivasertib blocks a molecule called AKT which is produced by cancer cells and encourages cancer to grow.
RE-AKT has several stages, or phases:
- Phase I established the best dose of capivasertib for participants to receive in combination with enzalutamide.
- Phase II investigated how well the combination of enzalutamide and capivasertib slowed participants’ cancer growth.